ArticleFrontiers in oncology2026
Case Report: Primary clear cell adenocarcinoma of the urethra-imaging features and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary clear cell adenocarcinoma of the urethra (PCCAU) is an extremely rare malignant tumor. Its clinical manifestations are nonspecific, and preoperative diagnosis relies primarily on imaging studies. To date, most reports on this disease are isolated case presentations, and systematic studies correlating imaging findings with pathological results remain scarce. Case presentation: A 58-year-old woman was admitted due to voiding dysfunction for 14 months, worsened with gross hematuria for 2 months. Preoperative imaging evaluation included ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI). US revealed an irregular hypoechoic mass in the post-bladder urethral region with minimal internal blood flow; CT scan indicated a heterogeneously enhancing mass in the urethral area accompanied by necrotic changes; MRI demonstrated a periurethral lesion showing a slightly high signal on T2-weighted imaging (T2WI) with a low-signal capsule. Diffusion-weighted imaging (DWI) showed restricted diffusion, with an apparent diffusion coefficient (ADC) value of 0.79 × 10 Conclusions: PCCAU is extremely rare. Imaging examinations, particularly multimodal MRI, combined with histopathological and immunohistochemical analyses, play a crucial role in its diagnosis. Early surgical intervention contributes to improved prognosis, and personalized treatment strategies, including immunotherapy, may offer clinical benefits in advanced cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.